About MeClinical Interest
Head and neck and thyroid cancers.
Pioneered the “Submandibular Salivary Gland Transfer Procedure” for the prevention of XRT induced xerostomia with Dr.
A phase II study to evaluate the effects of transfer
of a submandibular salivary gland to the submental region (outside of the radiation field) on xerostomia in head and neck cancer patients receiving radiation treatment. (Principal Investigator).
A phase II multi-center
study of submandibular salivary gland transfer to the submental space prior to start
of radiation treatment, for the prevention of XRT induced xerostomia in head and neck cancer patients. (Principal Investigator). RTOG – 0244.
A phase III randomized, multi-center Canadian study trial comparing oral pilocarpine (Salagen) vs. submandibular salivary gland transfer protocol, for the prevention of radiation (XRT) induced xerostomia in head and neck cancer patients. (Principal Investigator).
To study the impact of dental complications (DMFT Index, Gingival Index, Plaque Index, Streptococcus Mutans assay), secondary to XRT induced xerostomia in the two arms of the phase
III randomized study comparing oral Pilocarpine vs. submandibular salivary gland transfer protocol for the prevention of XRT induced xerostomia.
Prevention of xerostomia using the submandibular gland transfer procedure: Impact on functional outcomes (swallowing, speech) and quality of life, after treatment for head and neck cancer.
A phase I/II feasibility/efficacy study using Intensity-Modulated Radiation Therapy (IMRT) in Head and Neck (H & N) cancer patients to permit sparing of parotid gland function.
Collaboration with Department of Pharmacy, University of Alberta, on “Cellular Brachytherapy project.”